Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer
Objectives: Lung cancer accounts for 20% of cancer-related deaths worldwide. Several studies have shown that Vitamin D levels at the time of diagnosis are prognostic in lung cancer. In this study, we evaluated the relationship between pre-diagnosis Vitamin D replacement levels and platinum-based chemotherapy results. Methods: In this cross-sectional study, we retrospectively analyzed archive records of all 247 patients diagnosed with lung cancer from an oncology center in Turkey, between 2012-2018. The chemotherapy outcomes, Vitamin D levels and replacement doses of these patients up to 6 months ago were recorded. Results: Vitamin D levels of 153 patients were below 15 ng/mL, 65 patients had a level of 15-30 ng/mL, and 29 patients had a vitamin D level higher than 30 ng/mL. In the study population, 215 had a replacement below 300.000 IU whereas 32 had a replacement above 300.000 IU. When the patients were evaluated based on their chemotherapy responses, no difference was observed between the patients with below and above 300.000 IU. In our study, Vitamin D and replacement level at the time of diagnosis did not change the chemotherapy response. Conclusion: Vitamin D replacement levels were not significantly associated with chemotherapy outcomes in our study
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. [CrossRef]
2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977–1010. [CrossRef]
3. Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Ther Med 2011;2:181–193. [CrossRef]
4. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009;94:26–34. [CrossRef]
5. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
6. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, et al. Vitamin D is associated with improved survival in early-stage nonsmall cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14:2303–9. [CrossRef]
7. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin Dfor cancer prevention: global perspective. Ann Epidemiol 2009;19:468–83. [CrossRef]
8. Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, et al. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int 2009;104:909–14. [CrossRef]
9. Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. Cell Physiol Biochem 2015;36:299–305. [CrossRef]
10. Chen GC, Zhang ZL, Wan Z, Wang L, Weber P, Eggersdorfer M, et al. Circulating 25-hydroxyvitamin D and risk of lung cancer: a dose-response meta-analysis. Cancer Causes Control 2015;26:1719–28. [CrossRef]
11. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007;25:479–85. [CrossRef]
12. Ma Y, Yu WD, Trump DL, Johnson CS. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010;116:3294–303. [CrossRef]
13. Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, et al. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:2239–45. [CrossRef]
14. Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol 2011;123:30–6. [CrossRef]
15. Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-smallcell lung cancer. Clin Lung Cancer 2013;14:433–9. [CrossRef]
16. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009;29:3511–36.
17. Akiba T, Morikawa T, Odaka M, Nakada T, Kamiya N, Ya-mashita M, et al. Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Random-ized, Double-Blind, Placebo-Controlled Trial. Clin Cancer Res 2018;24:4089–97. [CrossRef]
18. Ma K, Xu W, Wang C, Li B, Su K, Li W. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy. Cancer Biomark 2017;18:297–303. [CrossRef]
19. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5596–602. [CrossRef]
20. Anic GM, Weinstein SJ, Mondul AM, Männistö S, Albanes D. Serum vitamin D, vitamin D binding protein, and lung cancersurvival. Lung Cancer 2014;86:297–303. [CrossRef]